Pfizer has selected the first drug candidate from a collaboration with Sosei Group to develop drugs for major diseases, which are aimed at targets from the G protein-coupled receptor (GPCR)
Allergan and Sosei’s experimental Alzheimer’s medicine has run into trouble – the companies have called a halt to trials after an unexpected toxicology finding in an animal study.<
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl
